Clinical activity of the anaplastic lymphoma kinase TKI alectinib in RET-rearranged NSCLC was firstly reported in two of four patients described by Lin et al. [60], successively in a case report [68] and in three among the four patients described in a case series [69]. This evidence concerns the gene ALK and non-small cell lung carcinoma.